Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Zacks Investment Research • 10/23/26
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 10/22/26
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121GlobeNewsWire • 10/05/26
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to BuyZacks Investment Research • 08/10/26
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/26
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/08/26
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/19/26
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 05/19/26
Korro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/07/26
Korro Announces Oral and Poster Presentations at Upcoming Scientific ConferencesGlobeNewsWire • 04/16/26
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost OutlookBenzinga • 03/13/26
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/12/26
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?Zacks Investment Research • 01/30/26
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/20/26